Phase I Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded to Standard Therapy.
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2013
At a glance
- Drugs Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ImClone Systems
- 19 Feb 2010 Actual patient number (37) added as reported by ClinicalTrials.gov.
- 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.